Xoma To Fund 25% Of hu1124 Phase III Trial With Genentech Loan
Executive Summary
Xoma will fund 25% of Phase III development costs for the monoclonal antibody hu1124 and receive 25% of product revenues according to a new agreement with Genentech announced April 15.